JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB263362

Human SPG11 knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

SPG11 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1 and 2 bp deletion in exon1.

View Alternative Names

Colorectal carcinoma-associated protein, DKFZp762B1512, FLJ21439, KIAA1840, SPTCS_HUMAN, Spastic paraplegia 11, Spastic paraplegia 11 (autosomal recessive), Spastic paraplegia 11 protein, Spatacsin

2 Images
Sanger Sequencing - Human SPG11 knockout HeLa cell lysate (AB263362)
  • Sanger seq

Unknown

Sanger Sequencing - Human SPG11 knockout HeLa cell lysate (AB263362)

Allele-1 : 2 bp deletion in exon1

Sanger Sequencing - Human SPG11 knockout HeLa cell lysate (AB263362)
  • Sanger seq

Unknown

Sanger Sequencing - Human SPG11 knockout HeLa cell lysate (AB263362)

Allele-2 : 1 bp deletion in exon1

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1 and 2 bp deletion in exon1.

Disease

Adenocarcinoma

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab263362-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human SPG11 knockout HeLa cell lysate", "number":"AB263362-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB263362-CMP02", "productcode":"" } ] } } }

Properties and storage information

Gene name
SPG11
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

SPG11 also known as spatacsin is a protein with a mass of approximately 249 kDa. This protein is expressed mainly in neural tissues including the brain and spinal cord. Mechanically SPG11 interacts with various other proteins contributing to the maintenance and function of the lysosomal compartment within cells. It plays an important role in membrane trafficking processes particularly in the vesicles involved in endocytosis and autophagy.
Biological function summary

In the context of neuronal health SPG11 is significant for the function of neurons. It forms part of a larger protein complex known as the AP-5 adaptin complex which assists in lysosomal positioning and function. By ensuring proper lysosomal function SPG11 supports neuronal maintenance and health. Issues with its function disrupt lysosomal degradation pathways and can have broad implications for neuron viability.

Pathways

SPG11 is essential in endolysosomal and autophagic pathways serving as a connection point for effective lysosomal transport. These pathways include interactions with proteins such as AP5Z1 and ZFYVE26 which collaborate to modulate lysosomal positioning and maintenance. SPG11's proper operation within these pathways allows for efficient cellular digestion of macromolecules and removal of damaged organelles critical for cellular health.

Mutations in SPG11 lead to rare neurological conditions like spastic paraplegia type 11 and some forms of juvenile amyotrophic lateral sclerosis (ALS). SPG11's mutation or dysfunction can result in improper lysosomal degradation contributing to the nervous system's degeneration. Related proteins like spastizin (ZFYVE26) and AP5Z1 when disrupted also exhibit similar symptoms of neural decay highlighting SPG11's integral role in neuronal disease mechanisms.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com